Tumor necrosis factor alpha (TNF-α) inhibitors are increasingly administered to children and
adolescents with juvenile idiopathic arthritis (JIA) and pediatric inflammatory bowel disease …

Objectives Anti-tumor necrosis factor alpha (anti-TNF-α) agents are generally well tolerated,
yet they can be associated with serious adverse events (SAEs) in a minority of patients. We …

Objectives TNF-α inhibitors (TNFIs) have a black box warning for increased risk of serious
infection that was based on evidence from studies of adults. Evidence of the association is …

Children and adolescents with inflammatory bowel disease (IBD) receiving therapy with
tumor necrosis factor α inhibitors (anti-TNFα) pose a unique challenge to health care …

Abstract Background Juvenile Idiopathic arthritis (JIA) is the most common chronic rheumatic
disease in childhood. The diagnosis is based on the underlying symptoms of arthritis with an …

Background & Aims Many physicians hesitate to recommend anti–tumor necrosis factor
(TNF) therapy for pediatric patients with inflammatory bowel disease (IBD) because of …

Objective To assess whether treatment with biologic response modifying agents during
clinical trial study periods increases the risk of serious infections in children with juvenile …

Objective To estimate the incidence rate (IR) of psoriasis in children with inflammatory bowel
disease (IBD), juvenile idiopathic arthritis (JIA), and chronic noninfectious osteomyelitis …

Background Inflammatory bowel disease can develop in the context of some rheumatic
diseases in childhood, including juvenile idiopathic arthritis (JIA). Inflammatory bowel …

Objective To examine the effects of tumor necrosis factor inhibitors on the risk for serious
infections and other influencing factors in a registry. Methods Patients exposed for the first …